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Primary Hyperaldosteronism  
Prof. Dr. Claudia E. Reusch, DiplECVIM-CA 
Aldosterone is secreted from the adrenal cortex under the control of the renin-angiotensin 
system and of potassium and to a lesser degree of ACTH. Its production is restricted to the 
zona glomerulosa because the enzyme aldosterone synthase is expressed zonal-specific. After 
secretion aldosterone binds to mineralocorticoid receptors which are present in the classical 
targets such as kidney, colon, sweat and salivary glands. Recently, it was shown that 
aldosterone is also synthesized in extra-adrenal tissues such as heart, brain and vasculature. In 
principle glucocorticoids and mineralocorticoids bind equally to the mineralocorticoid 
receptors, however, the enzyme 11β-hydroxysteroid dehydrogenase type 2 converts cortisol to 
the inactive cortisone, thereby preventing receptor-binding and enabling specificity of 
aldosterone action.  
The consequences of increased aldosterone concentration are retention of sodium and water in 
the distal and collecting tubules of the kidneys. This results in increased intravascular volume 
and increased urinary potassium and hydrogen excretion. Excessive concentrations of 
circulating aldosterone also induce vasoconstriction and lead to an increase in peripheral 
vascular resistance. Additionally, aldosterone has pro-inflammatory and pro-fibrotic 
properties, leading to vascular, cardiac and renal lesions in the case of aldosterone excess.  
The disease was first described in 1955 in a young woman by Jermone W. Conn, an American 
endocrinologist. The patient suffered from muscle spasm, weakness, hypertension and severe 
hypokalemia of several years duration. After extensive investigations over several months 
Conn came to the conclusion that the cause most likely was excessive secretion of 
aldosterone. In fact a tumor of the right adrenal gland was removed, which lead to complete 
recovery. Conn named the disease primary aldosteronisms, later it became also known as 
Conn's syndrome. After several years of research on this topic Conn postulated that primary 
aldosteronism is present in 10 – 20% of patients with hypertension: However, this was denied 
by most members of the medical profession who stated that the prevalence was less than 1%. 
Interestingly, a more systematic screening of hypertensive humans has recently shown that the 
prevalence is in fact much higher (5-10% of all patients with hypertension) and close to what 
has been assumed by Conn nearly half a century ago. In approximately 60% of human 
patients the disease is caused by bilateral idiopathic adrenal hyperplasia, while approximately 
35% have aldosterone-producing adenomas. In a few patients unilateral adrenal hyperplasia, 
aldosterone-producing carcinomas or a specific form of familial hyperaldosteronism is 
present. Typical findings are systemic hypertension, hypokalemia and metabolic acidosis. The 
degree of hypertension is usually moderate to severe, and patients with aldosteronoma tend to 
have higher blood pressure than patients with idiopathic aldosteronism. Due to the fact that 
screening for the disease is becoming more systematic and the diagnosis is generally made 
earlier, the prevalence of hypokalemia is decreasing, and nowadays the majority of human 
patients are normokalemic at the time of diagnosis.  
The first case of feline primary hyperaldosteronism was described in 1983. Since then, the 
disease has been diagnosed with increased frequency, and a little more than 30 cases have 
now been reported. Although no data are available concerning the true prevalence of the 
disease in the feline population, it is assumed that the disease is more common than initially 
thought. Feline primary hyperaldosteronism is a disease of middle aged to old cats (5 – 20 
years), there appears to be no breed or sex predilection. Clinical sings include those caused by 
a) hypokalemia (hypokalemic polymyopathy); such as cervical ventroflexion, hind limb 
weakness, ataxia or limb stiffness,  
b) hypertension; such as intraocular hemorrhage, mydriasis and blindness due retinal 
detachment and hemorrhage.   
Polyuria and polydipsia has also been seen in some cases, other non-specific signs such as 
anorexia, weight loss, lethargy, restlessness or panting may also be present. .  
In the majority of cats with primary aldosteronism the disease is caused by unilateral 
carcinomas or adenomas, while bilateral tumors and bilateral nodular hyperplasia are less 
common. In cats with bilateral nodular hyperplasia the course of the disease is usually milder 
than in cats with other forms.   
Almost all cats described to date have been hypokalemic at the time of diagnosis. However, as 
in human medicine, it may be possible that hyperaldosteronism is overlooked in cats with 
normal potassium levels. At our clinic we have recently seen cats which were normokalemic 
at presentation and hypokalemia was only seen after several days of hospitalization. A more 
systematic screening for primary hyperaldosteronism may improve diagnosis and thus 
increase the prevalence of the disease. Based on data available to date, the prevalence of 
hypertension in cats with primary aldosteronism appears to be high; the severity of 
hypertension ranged from mild to severe (185-270 mmHg).  
Aldosterone excess also leads to renal acid excretion and metabolicalkalosis, which is usually 
mild. Additionally, hypophosphatemia may be present. Hyperaldosteronisms is often 
associated with slowly progressive renal disease, most likely due to hypertension and the 
profibrotic effects of aldosterone. Renal disease seems to be particular common in cats with 
bilateral nodular hyperplasia. Primary hyperaldosteronism should be diagnosed by means of 
hormone testing and diagnostic imaging. Hormone testing includes the demonstration of 
increased aldosterone and suppressed plasma renin activity, and increased aldosterone:renin 
ratio. Measurement of aldosterone alone is often insufficient: in cases of adrenocortical tumor 
aldosterone is usually highly elevated, however in cases with bilateral nodular hyperplasia 
aldosterone often is only slightly elevated or high-normal. It is important to remember that 
aldosterone may also be high in dehydrated animals without the disease (= secondary 
hyperaldosteronism). The measurement of the plasma renin activity is technically demanding 
and availability of the test is limited. Additionally, strict sampling and storage conditions have 
to be followed. Unfortunately, measurement of renin activity cannot be replaced by 
measurement of renin concentration (which is readily available) due to the lack of detection of 
feline renin by the antibody. Other tests, such as the fludrocortisone suppression test have 
been described, however its diagnostic utility needs further investigation.  
Diagnostic imaging includes ultrasonography (or CT, MRI) of the abdomen with emphasis on 
the adrenal glands and possibly thoracic radiographs to search for metastasis. In cases in 
which the disease is due to an adrenal tumor usually the mass is easily found by 
ultrasonography. Very small masses, bilateral tumors and bilateral hyperplasia however pose 
a diagnostic challenge. Ultrasonography is also helpful to characterize extent of a tumor, 
possible invasion into the venal cava or other surrounding structures and metastasis.  
 
Initial treatment should be directed towards alleviation of hypertension and hypokalemia by 
using an aldosterone antagonist (spironolactone 2.5 mg/kg q24h or 6.25 mg/cat q12h PO) and 
a calcium channel blocker (amlodipine besylate 0.625-1.25 mg/cat q24h PO), and substituting 
potassium as needed. Subsequent adrenalectomy is the treatment of choice for animals 
without tumor metastasis. Adrenalectomy is potentially curative, however due to the risk of 
perioperative complications (e.g. hemorrhage) the interventions should only be performed by 
an experienced surgeon. In cases in which adrenalectomy is not feasible (e.g. metastasized 
tumor, bilateral tumor or hyperplasia), medical treatment with spironolactone and amlodipine 
besylate should be continued. The two drugs combined seem to lead to resolution of 
hypertension in most cases  
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